

Amendments to the Claims

1-17. (Cancelled)

18. (Currently amended) A method of ~~inhibiting~~ treating a mammal suffering from cerebral embolism-induced cerebrovascular hyperpermeability which comprises ~~administering an effective~~ injecting an amount of a hepatocyte growth factor ~~to a~~ into a cerebral ventricle of the mammal which amount is sufficient to ameliorate a symptom associated with embolism-induced disorder.

19-24. (Cancelled)

25. (Currently amended) The method according to claim 18, wherein the symptom is a decline in learning function, and the method results in an improvement in the a decline in learning function ~~is improved.~~

26. (Currently amended) The method according to claim 18, wherein the symptom is a decline in memory function, and the method results in an improvement in the a decline in memory function ~~is improved.~~

27. (Currently amended) The method according to claim 18, wherein the symptom is dementia, and the method results in an improvement in the dementia ~~is improved.~~

28. (New) The method according to claim 18, wherein the mammal has a cerebral edema.